Universe Pharmaceuticals Inc.
UPC · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -9.7% | -21.3% | -6.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 34.6% | 27.9% | 25.2% | 29.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -25.4% | -61.9% | -13.5% | -26.6% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -35.9% | 43.1% | -101.7% | -39.4% |
| EPS | -944.4 | 719.79 | -2,155.91 | -919.74 |
| % Growth | -231.2% | 133.4% | -134.4% | – |
| EPS Diluted | -944.4 | 719.79 | -2,155.91 | -919.74 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -31.5% | 46.3% | -93.5% | -27.5% |